TipRanks on MSN

Alpha Tau Medical unveils strong pancreatic cancer Alpha DaRT data ahead of ASCO GI 2026

An update from Alpha Tau Medical Ltd ( ($DRTS) ) is now available. On January 6, 2026, Alpha Tau Medical reported final results from its ...

Alpha Tau Submits First Pre-Market Approval Module to the FDA for Alpha DaRT(R) for the Treatment of Recurrent Cutaneous Squamous Cell Carcinoma (cSCC)

Founded in 2016, Alpha Tau is an Israeli oncology therapeutics company that focuses on research, development, and potential commercialization of the Alpha DaRT for the treatment of solid tumors. The ...

Alpha Tau Reports New Positive Results in Two Upcoming Presentations at ASCO GI 2026 Symposium Showcasing Immune-Preservation and High Disease Control in M…

Final results from first pancreatic cancer study in Montreal demonstrate 81% disease control rate, or 87% excluding the first ...
Nasdaq

Alpha Tau Medical Reports Strong Interim Clinical Data for Alpha DaRT® in Pancreatic Cancer and Other Tumors

Alpha Tau reports promising Alpha DaRT trial results in pancreatic cancer and head and neck cancer, with significant survival benefits. High disease control rate (91% DCR) and positive interim safety ...